Correction to: Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

被引：0

作者：

Barbara Schwartzberg

John Lewin

Osama Abdelatif

Jacqueline Bernard

Hanadi Bu-Ali

Simon Cawthorn

Margaret Chen-Seetoo

Sheldon Feldman

Sasirekha Govindarajulu

Lyn Jones

Arne Juette

Sanjay Kavia

Robert Maganini

Simon Pain

Mike Shere

Craig Shriver

Simon Smith

Alexandra Valencia

Eric Whitacre

Roger Whitney

机构：

[1] Sarah Cannon Research Institute at Rose Medical Center,

[2] Women’s Imaging Center,undefined

[3] Tucson Pathology Associates,undefined

[4] Walter Reed National Military Medical Center,undefined

[5] Virginia Piper Cancer Institute,undefined

[6] Southmead Hospital,undefined

[7] Herbert Irving Pavilion,undefined

[8] Columbia University,undefined

[9] Montefiore Einstein Center for Cancer Care,undefined

[10] Norfolk and Norwich University Hospital,undefined

[11] Broomfield Hospital,undefined

[12] St. Alexius Breast Care Center,undefined

[13] Breast Center of Southern Arizona,undefined

来源：

Annals of Surgical Oncology | 2018年 / 25卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The article “Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations”, written by Barbara Schwartzberg et al., was originally published electronically on the publisher’s internet portal (currently SpringerLink) on July 9, 2018, without open access.

引用

页码：998 / 998

共 50 条

[31] A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)
Litton, J.
Symmans, F.
Gogineni, K.
Saltzman, M.
Telli, M. L.
Usha, L.
Chakrabarti, J.
Tudor, I. C.
Quek, R. G.
Czibere, A.
CANCER RESEARCH, 2019, 79 (04)
[32] First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer
Dragun, A. E.
Ajkay, N. J.
Riley, E. C.
Roberts, T.
Pan, J.
Rai, S. N.
Jain, D.
Quillo, A. R.
Scoggins, C. R.
McMasters, K. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S7 - S7
[33] First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer
Dragun, Anthony E.
Ajkay, Nicholas J.
Riley, Elizabeth C.
Roberts, Teresa L.
Pan, Jianmin
Rai, Shesh N.
Jain, Dharamvir
Quillo, Amy R.
Scoggins, Charles R.
McMasters, Kelly M.
Woo, Shiao Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (03): : 595 - 602
[34] HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Llombart-Cussac, Antonio
Cortes, Javier
Pare, Laia
Galvan, Patricia
Bermejo, Begona
Martinez, Noelia
Vidal, Maria
Pernas, Sonia
Lopez, Rafael
Munoz, Montserrat
Nuciforo, Paolo
Morales, Serafin
Oliveira, Mafalda
de la Pena, Lorena
Pelaez, Alexandra
Prat, Aleix
LANCET ONCOLOGY, 2017, 18 (04): : 545 - 554
[35] OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer
Balmana, Judith
Dymond, Mike
Lowe, Elizabeth S.
Lukashchuk, Natalia
Winter, Maria
Tung, Nadine
CANCER RESEARCH, 2023, 83 (05)
[36] Multicenter clinical trial of percutaneous laser ablation for early stage primary breast cancer. Results of 49 cases with radiographic and pathological correlation
Schwartzberg, B. S.
Abdelatif, O. M. A.
Lewin, J. M.
Bernard, J. M.
Brehm, J. L.
Bu-Ali, H. M.
Cawthorn, S. J.
Chen-Seeto, M.
Feldman, S. M.
Govindarajulu, S.
Jones, L. I.
Juette, A.
Kavia, S.
Maganini, R. O.
Pain, S. J.
Shere, M. H.
Shriver, C. D.
Smith, S. G.
Valencia, A.
Whitacre, E. B.
Whitney, R.
CANCER RESEARCH, 2016, 76
[37] Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
Jones, Stephen E.
Collea, Rufus
Paul, Devchand
Sedlacek, Scot
Favret, Anne M.
Gore, Ira, Jr.
Lindquist, Deborah L.
Holmes, Frankie Ann
Allison, Mary Ann K.
Brooks, Barry D.
Portillo, Raul M.
Vukelja, Svetislava J.
Steinberg, Michael S.
Stokoe, Christopher
Crockett, Maria W.
Wang, Yunfei
Asmar, Lina
Robert, Nicholas J.
O'Shaughnessy, Joyce
LANCET ONCOLOGY, 2013, 14 (11): : 1121 - 1128
[38] Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial
Zhang, Liulu
Wu, Zhi-Yong
Li, Jie
Lin, Ying
Liu, Zhenzhen
Cao, Yin
Zhang, Gangling
Gao, Hong-Fei
Yang, Mei
Yang, Ci-Qiu
Zhu, Teng
Cheng, Min-Yi
Ji, Fei
Li, Jieqing
Wang, Kun
INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 654 - 662
[39] Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
Belkouz, Ali
de Vos-Geelen, Judith
Mathot, Ron A. A.
Eskens, Ferry A. L. M.
van Gulik, Thomas M.
van Oijen, Martijn G. H.
Punt, Cornelis J. A.
Wilmink, Johanna W.
Klumpen, Heinz-Josef
BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 634 - 639
[40] Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
Ali Belkouz
Judith de Vos-Geelen
Ron A. A. Mathôt
Ferry A. L. M. Eskens
Thomas M. van Gulik
Martijn G. H. van Oijen
Cornelis J. A. Punt
Johanna W. Wilmink
Heinz-Josef Klümpen
British Journal of Cancer, 2020, 122 : 634 - 639

← 1 2 3 4 5 →